At a glance
- Originator Fujisawa
- Class Heart failure therapies
- Mechanism of Action Vasopressin V2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Heart failure
Most Recent Events
- 23 Jun 1998 Commercial data has been reviewed by Fujisawa
- 27 Apr 1998 Preclinical development for Congestive heart failure in Japan (Unknown route)